Search Results - "Huckriede, Anke L. W"

The COVID HOME study research protocol: Prospective cohort study of non-hospitalised COVID-19 patients by Tami, Adriana, van der Gun, Bernardina T. F, Wold, Karin I, Vincenti-González, María F, Veloo, Alida C. M, Knoester, Marjolein, Harmsma, Valerie P. R, de Boer, Gerolf C, Huckriede, Anke L. W, Pantano, Daniele, Gard, Lilli, Rodenhuis-Zybert, Izabela A, Upasani, Vinit, Smit, Jolanda, Dijkstra, Akkelies E, de Haan, Jacco J, van Elst, Jip M, van den Boogaard, Jossy, O' Boyle, Shennae, Nacul, Luis, Niesters, Hubert G. M, Friedrich, Alex W

“…Background Guidelines on COVID-19 management are developed as we learn from this pandemic. However, most research has been done on hospitalised patients and…”
Get full text

Performance Testing of a Homemade Aerosol Generator for Pulmonary Administration of Dry Powder Formulations to Mice by Heida, Rick, Hagedoorn, Paul, van Meel, Melle C, Prins, Jurrie E R, Simonis, Frederike S, Akkerman, Renate, Huckriede, Anke L W, Frijlink, Henderik W, de Boer, Anne H, Hinrichs, Wouter L J

“…A challenge in the development of dry powder formulations for inhalation is the poor reproducibility of their administration to small laboratory animals. The…”
Get full text

A Single Injection with Sustained-Release Microspheres and a Prime-Boost Injection of Bovine Serum Albumin Elicit the Same IgG Antibody Response in Mice by van der Kooij, Renée S, Beukema, Martin, Huckriede, Anke L W, Zuidema, Johan, Steendam, Rob, Frijlink, Henderik W, Hinrichs, Wouter L J

“…Although vaccination is still considered to be the cornerstone of public health care, the increase in vaccination coverage has stagnated for many diseases…”
Get full text

Effect of DMARDs on the immunogenicity of vaccines by van Sleen, Yannick, van der Geest, Kornelis S. M., Huckriede, Anke L. W., van Baarle, Debbie, Brouwer, Elisabeth

“…Vaccines are important for protecting individuals at increased risk of severe infections, including patients undergoing DMARD therapy. However, DMARD therapy…”
Get full text

COVID-19 vaccination: the VOICE for patients with cancer by van der Veldt, Astrid A. M., Oosting, Sjoukje F., Dingemans, Anne-Marie C., Fehrmann, Rudolf S. N., GeurtsvanKessel, Corine, Jalving, Mathilde, Rimmelzwaan, Guus F., Kvistborg, Pia, Blank, Christian U., Smit, Egbert F., Lemmens, Valery E. E. P., Hiltermann, T. Jeroen N., Koopmans, Marion P. G., Huckriede, Anke L. W., Rots, Nynke Y., van Els, Cecile A. C. M., van Baarle, Debbie, Haanen, John B. A. G., de Vries, Elisabeth G. E.

Get full text

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming by Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Geers, Daryl, Schmitz, Katharina S., Garcia Garrido, Hannah M., Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Lafeber, Melvin, van Baarle, Debbie, GeurtsvanKessel, Corine H., de Vries, Rory D., van der Kuy, P. Hugo M.

“…A trial involving 434 participants examined the effects of no boosting or of boosting with one of the three approved Covid-19 vaccines — Ad26.COV2.S,…”
Get full text

GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults by Behzad, Hayedeh, Huckriede, Anke L. W., Haynes, Laura, Gentleman, Beth, Coyle, Krysta, Wilschut, Jan C., Kollmann, Tobias R., Reed, Steven G., McElhaney, Janet E.

“…Background. The decline in influenza vaccine efficacy in older adults is associated with a limited ability of current split-virus vaccines (SVVs) to stimulate…”
Get full text

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol by Sablerolles, Roos S G, Goorhuis, Abraham, GeurtsvanKessel, Corine H, de Vries, Rory D, Huckriede, Anke L W, Koopmans, Marion P G, Lafeber, Melvin, Postma, Douwe F, van Baarle, Debbie, Visser, Leo G, Dalm, Virgil A S H, Kootstra, Neeltje A, Rietdijk, Wim J R, van der Kuy, P Hugo M

Get full text

Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro by Heida, Rick, Born, Philip A., Tapia-Calle, Gabriela, Frijlink, Henderik W., Salvati, Anna, Huckriede, Anke L. W., Hinrichs, Wouter L. J.

“…Viral subunit vaccines are a safer and more tolerable alternative to whole inactivated virus vaccines. However, they often come with limited efficacy,…”
Get full text

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol by Tan, Ngoc H, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, Geers, Daryl, Zaeck, Luca M, Koopmans, Marion P G, Dalm, Virgil A S H, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Lafeber, Melvin, GeurtsvanKessel, Corine H, de Vries, Rory D, van der Kuy, Paul-Hugo Marie

“…Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital…”
Get full text

Development of an Orodispersible Film Containing Stabilized Influenza Vaccine by Tian, Yu, Bhide, Yoshita C, Woerdenbag, Herman J, Huckriede, Anke L W, Frijlink, Henderik W, Hinrichs, Wouter L J, Visser, J Carolina

“…Most influenza vaccines are administered via injection, which is considered as user-unfriendly. Vaccination via oral cavity using an orodispersible film (ODF)…”
Get full text

An Efficient UV-C Disinfection Approach and Biological Assessment Strategy for Microphones by Vignali, Valentina, Hoff, Tobi, de Vries-Idema, Jacqueline J., Huckriede, Anke L. W., van Dijl, Jan Maarten, van Rijn, Patrick

“…Hygiene is a basic necessity to prevent infections, and though it is regarded as vital in general, its importance has been stressed again during the pandemic…”
Get full text

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial by Oosting, Sjoukje F, van der Veldt, Astrid A M, GeurtsvanKessel, Corine H, Fehrmann, Rudolf S N, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, van der Heiden, Marieke, Rimmelzwaan, Guus F, Kvistborg, Pia, Blank, Christian U, Koopmans, Marion P G, Huckriede, Anke L W, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, de Vries, Elisabeth G E

“…Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the…”
Get full text

Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice by Mandviwala, Ahmedali S., Huckriede, Anke L.W., Arankalle, Vidya A., Patil, Harshad P.

“…RSV infection remains a serious threat to the children all over the world, especially, in the low-middle income countries. Vaccine delivery via the mucosa…”
Get full text

Advances in the development of entry inhibitors for sialic-acid-targeting viruses by Heida, Rick, Bhide, Yoshita C., Gasbarri, Matteo, Kocabiyik, Özgün, Stellacci, Francesco, Huckriede, Anke L.W., Hinrichs, Wouter L.J., Frijlink, Henderik W.

“…•Entry inhibitors might overcome the limitation of viral mutation.•Antiviral research benefits from a broad-spectrum approach.•Sialic acids can serve as a…”
Get full text

Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug by Heida, Rick, Jacob Silva, Paulo H., Akkerman, Renate, Moser, Jill, de Vries-Idema, Jacqueline, Bornet, Aurélien, Pawar, Sujeet, Stellacci, Francesco, Frijlink, Henderik W., Huckriede, Anke L.W., Hinrichs, Wouter L.J.

“…[Display omitted] Increasing resistance to antiviral drugs approved for the treatment of influenza urges the development of novel compounds. Ideally, this…”
Get full text

Development of an inhalable antiviral powder formulation against respiratory syncytial virus by Heida, Rick, Akkerman, Renate, Jacob Silva, Paulo H., Lakerveld, Anke J., Ortiz, Daniel, Bigogno, Chiara, Gasbarri, Matteo, van Kasteren, Puck B., Stellacci, Francesco, Frijlink, Henderik W., Huckriede, Anke L.W., Hinrichs, Wouter L.J.

“…Respiratory viruses including the respiratory syncytial virus (RSV) aggravate the global burden of virus-inflicted morbidity and mortality. Entry inhibitors…”
Get full text

Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial by Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, van der Kuy, P Hugo M

“…Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron spike (S) protein were developed as a countermeasure against antigenically distinct…”
Get full text

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers by Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Schmitz, Katharina S, Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P G, Dalm, Virgil A S H, Kootstra, Neeltje A, Huckriede, Anke L W, Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H

“…The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after…”
Get full text

The COVID HOME study research protocol: Prospective cohort study of non-hospitalised COVID-19 patients by Adriana Tami, Bernardina T. F. van der Gun, Karin I. Wold, María F. Vincenti-González, Alida C. M. Veloo, Marjolein Knoester, Valerie P. R. Harmsma, Gerolf C. de Boer, Anke L. W. Huckriede, Daniele Pantano, Lilli Gard, Izabela A. Rodenhuis-Zybert, Vinit Upasani, Jolanda Smit, Akkelies E. Dijkstra, Jacco J. de Haan, Jip M. van Elst, Jossy van den Boogaard, Shennae O’ Boyle, Luis Nacul, Hubert G. M. Niesters, Alex W. Friedrich

“…Background Guidelines on COVID-19 management are developed as we learn from this pandemic. However, most research has been done on hospitalised patients and…”
Get full text